SMT201300007B - Trattamento di una malattia respiratoria - Google Patents

Trattamento di una malattia respiratoria

Info

Publication number
SMT201300007B
SMT201300007B SM201300007T SM201300007T SMT201300007B SM T201300007 B SMT201300007 B SM T201300007B SM 201300007 T SM201300007 T SM 201300007T SM 201300007 T SM201300007 T SM 201300007T SM T201300007 B SMT201300007 B SM T201300007B
Authority
SM
San Marino
Prior art keywords
treatment
respiratory disease
respiratory
disease
Prior art date
Application number
SM201300007T
Other languages
English (en)
Inventor
Harry Finch
Craig Fox
Mohammed Sajad
Original Assignee
Pulmagen Therapeutics Inflammation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0814488A external-priority patent/GB0814488D0/en
Priority claimed from GB0823568A external-priority patent/GB0823568D0/en
Application filed by Pulmagen Therapeutics Inflammation Ltd filed Critical Pulmagen Therapeutics Inflammation Ltd
Publication of SMT201300007B publication Critical patent/SMT201300007B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SM201300007T 2008-08-07 2013-01-17 Trattamento di una malattia respiratoria SMT201300007B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0814488A GB0814488D0 (en) 2008-08-07 2008-08-07 Respiratory disease treatment
GB0823568A GB0823568D0 (en) 2008-12-24 2008-12-24 Respiratory disease treatment
PCT/GB2009/001920 WO2010015818A1 (en) 2008-08-07 2009-08-05 Respiratory disease treatment

Publications (1)

Publication Number Publication Date
SMT201300007B true SMT201300007B (it) 2013-03-08

Family

ID=41202662

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201300007T SMT201300007B (it) 2008-08-07 2013-01-17 Trattamento di una malattia respiratoria

Country Status (21)

Country Link
EP (1) EP2222272B1 (it)
JP (1) JP5689797B2 (it)
CN (1) CN102170864B (it)
AU (1) AU2009279077C1 (it)
BR (1) BRPI0917567A2 (it)
CA (1) CA2733440C (it)
CY (1) CY1113744T1 (it)
DK (1) DK2222272T3 (it)
EA (1) EA019339B1 (it)
ES (1) ES2399179T3 (it)
GB (1) GB2465897B (it)
HR (1) HRP20130052T1 (it)
IL (1) IL210959A0 (it)
MX (1) MX2011001418A (it)
NZ (1) NZ590774A (it)
PL (1) PL2222272T3 (it)
PT (1) PT2222272E (it)
SI (1) SI2222272T1 (it)
SM (1) SMT201300007B (it)
WO (1) WO2010015818A1 (it)
ZA (1) ZA201100750B (it)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3205644A1 (en) 2005-12-29 2017-08-16 Celtaxsys Inc. Diamine derivatives as inhibitors of leukotriene a4 hydrolase
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
GB0913672D0 (en) 2009-08-05 2009-09-16 Argenta Discovery Ltd Glitazones
US8912335B2 (en) * 2009-12-15 2014-12-16 Metabolic Solutions Development Company, Llc PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases
GB2477540A (en) * 2010-02-05 2011-08-10 Argenta Therapeutics Ltd Respiratory disease treatment
WO2011098746A1 (en) * 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) * 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB2477743A (en) * 2010-02-10 2011-08-17 Argenta Therapeutics Ltd Enantiomers of 5-methyl-thiazolidine-2,4-dione glitazone compounds
GB201002224D0 (en) * 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
AU2014249168B2 (en) * 2013-03-12 2018-07-12 Celltaxis, Llc Methods of inhibiting leukotriene A4 hydrolase
CA2941562C (en) 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
AU2014240042C1 (en) 2013-03-14 2019-09-05 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
ES2831326T3 (es) 2014-01-15 2021-06-08 Poxel Sa Métodos para tratar trastornos neurológicos, metabólicos y otros mediante el uso de pioglitazona enantiopura enriquecida con deuterio
JP2017527618A (ja) * 2014-09-08 2017-09-21 ゴッサム バイオファーマシューティカルズ，インコーポレイティド 肺サルコイドーシスの治療方法
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
DK3439667T3 (da) * 2016-04-05 2024-04-02 Immune Sensor Llc Cgas antagonist forbindelser
KR101841589B1 (ko) * 2016-12-02 2018-03-23 주식회사 종근당 로베글리타존을 유효성분으로 포함하는 섬유증 예방 또는 치료용 약학적 조성물
WO2019213611A1 (en) 2018-05-04 2019-11-07 Cirius Therapeutics, Inc. Thiazolidinedione analogs for the treatment of nafld and metabolic diseases
EP3801559B1 (en) 2018-05-31 2025-01-01 Celltaxis, LLC Method of reducing pulmonary exacerbations in respiratory disease patients
CA3129405A1 (en) 2019-02-08 2020-08-13 United States Government As Represented By The Department Of Veterans Affairs Growth hormone-releasing hormone antagonists and uses thereof
WO2021011874A1 (en) * 2019-07-18 2021-01-21 University Of Miami Ghrh antagonists for use in a method of treating sarcoidosis
US20210315937A1 (en) * 2020-04-08 2021-10-14 University Of South Florida Methods of treating inflammation
WO2021212054A1 (en) * 2020-04-17 2021-10-21 Cirius Therapeutics, Inc. Methods and compositions for treating subjects with metabolic disorders and coronavirus infections
CN116390725A (zh) * 2020-04-30 2023-07-04 米尼奥尔克斯治疗有限公司 用于治疗肺部炎症和间质性肺病的羟基吡格列酮
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
KR20230116786A (ko) * 2020-12-01 2023-08-04 리버스피에이에이치 엘엘씨 만성 폐쇄성 폐질환, 천식, 폐렴, 기관지염, 낭포성 섬유증, 폐부종, 간질성 폐 질환, 사르코이드증, 특발성 폐섬유증, 급성 호흡곤란 증후군 및 폐동맥 고혈압을 치료하기 위한 방법 및 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2335597A (en) * 1998-03-27 1999-09-29 Glaxo Group Ltd Stereoisomers of Troglitazone in the Treatment of Diabetes
US6127394A (en) * 1999-03-08 2000-10-03 The University Of Mississippi 1,2-Dithiolane derivatives
GB9908647D0 (en) * 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
WO2002013812A1 (en) * 2000-08-17 2002-02-21 Pershadsingh Harrihar A Methods for treating inflammatory diseases
US20060013775A1 (en) * 2001-11-26 2006-01-19 Gristwood Robert W Use of ppar activators for the treatment of pulmonary fibrosis
US7981915B2 (en) * 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
JP2005200419A (ja) * 2004-01-16 2005-07-28 National Health Research Inst 癌治療法
WO2007100027A1 (ja) * 2006-03-02 2007-09-07 Daiichi Sankyo Company, Limited 光学活性なチアゾリジンジオン誘導体

Also Published As

Publication number Publication date
NZ590774A (en) 2012-09-28
CA2733440A1 (en) 2010-02-11
SI2222272T1 (sl) 2013-03-29
AU2009279077B2 (en) 2014-07-03
CY1113744T1 (el) 2016-06-22
JP5689797B2 (ja) 2015-03-25
JP2011529953A (ja) 2011-12-15
ES2399179T3 (es) 2013-03-26
WO2010015818A1 (en) 2010-02-11
DK2222272T3 (da) 2013-02-11
CN102170864A (zh) 2011-08-31
CA2733440C (en) 2016-06-28
PT2222272E (pt) 2013-01-29
HK1156501A1 (en) 2012-06-15
CN102170864B (zh) 2015-04-01
IL210959A0 (en) 2011-04-28
AU2009279077A1 (en) 2010-02-11
HRP20130052T1 (hr) 2013-02-28
ZA201100750B (en) 2012-06-27
MX2011001418A (es) 2011-07-20
GB2465897B (en) 2011-02-09
BRPI0917567A2 (pt) 2015-11-17
EP2222272A1 (en) 2010-09-01
EA201100305A1 (ru) 2011-10-31
PL2222272T3 (pl) 2013-04-30
GB2465897A (en) 2010-06-09
EP2222272B1 (en) 2012-11-07
AU2009279077C1 (en) 2014-12-04
GB201000468D0 (en) 2010-02-24
EA019339B1 (ru) 2014-02-28

Similar Documents

Publication Publication Date Title
NL301305I2 (nl) Vibegron of een farmaceutisch aanvaardbaar zout daarvan
NL301166I2 (nl) Avacopan of een farmaceutisch aanvaardbaar zout daarvan
NL301071I2 (nl) alpelisib of een farmaceutisch aanvaardbaar zout ervan
DK2222272T3 (da) Behandling af luftvejssygdom
IL246697A0 (en) Multiple exon skipping compositions for use in treating muscular dystrophy
PL2257305T3 (pl) Nowy farmaceutyczny preparat do leczenia stanu przedrzucawkowego
EP2296593A4 (en) MEDICAL HEAD COVER
EP2341974A4 (en) CATHETER ARRANGEMENT
BRPI0906366A2 (pt) Inalador
BRPI0914817A2 (pt) inalador
DK2330887T3 (da) Behandlingsindretning
HRP20181767T1 (hr) Postupak proizvodnje zubarskog pribora
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
PL2435825T3 (pl) Sposoby leczenia chorób
BRPI0906779A2 (pt) Inalador
FI20085693A0 (fi) Biosignaalin prosessointi
DK2173831T3 (da) Brøndbehandling
EP2052757A4 (en) MEDICAL CAPSULE
SMT201400053B (it) Forme farmaceutiche orali di bendamustina
EP3381471C0 (en) PAIN TREATMENT
BRPI0906367A2 (pt) inalador
HRP20160577T1 (hr) Liječenje osteoartritisa
FI20096402A0 (fi) Veriryhmästatuksen käyttö II
BRPI0906369A2 (pt) Inalador
PT3133396T (pt) Métodos de tratamento utilizando fármacos eliminadores de amoníaco